Suppr超能文献

存在终末期竞争风险时治疗效果量化与解读的实用建议:综述

Practical Recommendations on Quantifying and Interpreting Treatment Effects in the Presence of Terminal Competing Risks: A Review.

作者信息

McCaw Zachary R, Claggett Brian Lee, Tian Lu, Solomon Scott D, Berwanger Otavio, Pfeffer Marc A, Wei Lee-Jen

机构信息

Google, Mountain View, California.

Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

出版信息

JAMA Cardiol. 2022 Apr 1;7(4):450-456. doi: 10.1001/jamacardio.2021.4932.

Abstract

IMPORTANCE

In a comparative trial, the time to a clinical event is often a key end point. However, the occurrence of a terminal event, such as death or premature study discontinuation, may preclude observation of this outcome. Although various methods for handling competing risks are available, no specific recommendations have been made for scenarios encountered in practice, especially when the terminal event profiles of the study arms are dissimilar. Moreover, appropriate methods for a desirable outcome, such as live hospital discharge, have seldom been discussed.

OBSERVATIONS

Several of the most commonly used methods are reviewed. The first regards the terminal event as censoring and applies standard survival analysis to the event of interest. The between-group difference is usually summarized by the cause-specific hazard ratio. This summary measure is inappropriate when the new therapy markedly prolongs time to the terminal event. Moreover, the corresponding Kaplan-Meier curve for the end point of interest is uninterpretable. The second method is to use the cumulative incidence curve, which is the probability of experiencing the event of interest by each time point, acknowledging that patients who have died will never experience the event. However, the resulting pseudo hazard ratio is difficult to interpret. With a proper alternative summary measure, this approach works well for a desirable outcome but may not for an undesirable outcome. The third method focuses on the event-free survival time by combining information from occurrences of the terminal event and the event of interest simultaneously. This clinically interpretable method naturally accounts for differences in terminal event rates when comparing treatments with respect to the time to an undesirable outcome.

CONCLUSIONS AND RELEVANCE

This article enhances our understanding of each method's advantages and shortcomings and assists practitioners in choosing appropriate methods for handling competing risk problems in practice.

摘要

重要性

在一项比较试验中,临床事件发生时间通常是关键终点。然而,诸如死亡或提前终止研究等终末事件的发生可能会妨碍对这一结果的观察。尽管有多种处理竞争风险的方法,但对于实际中遇到的情况,尤其是当研究组的终末事件特征不同时,尚未给出具体建议。此外,对于诸如出院存活等理想结局的恰当方法也鲜有讨论。

观察结果

对几种最常用的方法进行了综述。第一种方法将终末事件视为删失,并对感兴趣的事件应用标准生存分析。组间差异通常用特定病因风险比来概括。当新疗法显著延长至终末事件的时间时,这种汇总指标是不合适的。此外,感兴趣终点的相应Kaplan-Meier曲线无法解读。第二种方法是使用累积发病率曲线,即每个时间点发生感兴趣事件的概率,承认已死亡的患者永远不会经历该事件。然而,由此得到的伪风险比难以解释。采用适当的替代汇总指标时,这种方法对于理想结局效果良好,但对于不良结局可能并非如此。第三种方法通过同时结合终末事件和感兴趣事件发生情况的信息来关注无事件生存时间。这种具有临床可解释性的方法在比较不同治疗方案在至不良结局时间方面的差异时,自然地考虑了终末事件发生率的差异。

结论与意义

本文增进了我们对每种方法优缺点的理解,并有助于从业者在实践中选择处理竞争风险问题的合适方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验